摘要
目的探讨白三烯拮抗剂扎鲁司特联合吸入舒利迭与单纯吸入舒利迭治疗老年哮喘的疗效。方法实验组31例老年哮喘患者吸入舒利迭,早晚各一次,口服扎鲁司特20 mg,2次/d;对照组22例患者吸入舒利迭,早晚各一次。疗程均为4 w。观察肺功能、血清白细胞介素(IL)-12、IL-13及生存质量的变化。结果治疗后实验组的一秒用力呼出量(FEV1%)及呼气峰流速(PEF%)高于对照组(P<0.01)。治疗后两组哮喘患者血清IL-12升高而IL-13降低,且实验组IL-13低于对照组(P<0.05)。治疗后实验组的活动受限、哮喘症状及心理状况的得分均高于对照组(P<0.01)。结论白三烯拮抗剂联合吸入舒利迭在改善轻、中度老年哮喘患者的肺功能、生存质量及纠正IL-12/IL-13失衡方面比单纯吸入舒利迭具有更好的效果。
Objective To compare the efficacy of leukotriene receptor antagonist Zafirlukast combination inhaled corticosteroids（ICS） with ICS in senile asthmatic patients.Methods 31 patients in experimental group took orally Zafirlukast 20 mg and twice every day and inhaled Beclometasone Dipropionate Aerosol 250 μg and three times every day.22 patients in normal group inhaled Beclometasone Dipropionate Aerosol 250 μg and three times every day.Course of treatment of all patients was 4 weeks.Pulmonary function,living quality and interleukin（IL）-12 and IL-13 in blood serum were respectively detected before and after accepting treatment.Results FEV1% and PEF% after therapy in the experimental group were significantly higher than those of normal group（P0.01）. After therapy,IL-12 in blood serum was higher,while IL-13 was lower in two groups.IL-13 after therapy in experimental group was lower than that of normal group（P0.05）.Scores on three scales of AQLQ were significantly higher in experimental group compared to normal group after therapy（P0.01）.Conclusions Leukotriene receptor antagonist combination ICS can improve pulmonary function,living quality and accommodate disequilibrium of IL-12/IL-13 for mild and moderate senile asthma patients,and is more effective than ICS alone.
出处
《中国老年学杂志》
CAS
CSCD
北大核心
2011年第1期7-9,共3页
Chinese Journal of Gerontology
基金
广西壮族自治区卫生厅课题(Z2005228)
关键词
老年性哮喘患者
白三烯拮抗剂
舒利迭
Senile asthmatic patients
Leukotriene receptor antagonist
Corticosteroids
